Technical Analysis for GLTO - Galecto, Inc.

Grade Last Price % Change Price Change
D 0.77 -5.56% -0.05
GLTO closed down 5.56 percent on Monday, March 18, 2024, on 23 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Support Bullish -5.56%
Wide Bands Range Expansion -5.56%
MACD Bearish Signal Line Cross Bearish -0.55%
20 DMA Support Bullish -0.55%
Hammer Candlestick Bullish -0.55%
NR7 Range Contraction -0.55%
NR7-2 Range Contraction -0.55%
Doji - Bullish? Reversal -0.55%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 16 hours ago
10 DMA Resistance about 20 hours ago
Down 3% about 20 hours ago
Down 2 % about 20 hours ago
Down 1% about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Galecto, Inc. Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Breakthrough Therapy Non Alcoholic Fatty Liver Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Progressive Fibrosis mTOR Fibrotic Disease Lectins Lung Diseases Treatment Of Fibrosis Copenhagen Galectin Myelofibrosis Galectin 3 Galecto Biotech

Is GLTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.7
52 Week Low 0.5
Average Volume 268,624
200-Day Moving Average 1.12
50-Day Moving Average 0.70
20-Day Moving Average 0.77
10-Day Moving Average 0.81
Average True Range 0.08
RSI (14) 52.38
ADX 22.92
+DI 20.43
-DI 13.40
Chandelier Exit (Long, 3 ATRs) 0.70
Chandelier Exit (Short, 3 ATRs) 0.87
Upper Bollinger Bands 0.91
Lower Bollinger Band 0.62
Percent B (%b) 0.52
BandWidth 38.52
MACD Line 0.03
MACD Signal Line 0.04
MACD Histogram -0.0047
Fundamentals Value
Market Cap 20.94 Million
Num Shares 27.1 Million
EPS -1.76
Price-to-Earnings (P/E) Ratio -0.44
Price-to-Sales 0.00
Price-to-Book 0.44
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.84
Resistance 3 (R3) 0.85 0.84 0.83
Resistance 2 (R2) 0.84 0.82 0.83 0.83
Resistance 1 (R1) 0.80 0.81 0.80 0.80 0.82
Pivot Point 0.79 0.79 0.78 0.78 0.79
Support 1 (S1) 0.76 0.77 0.75 0.75 0.72
Support 2 (S2) 0.74 0.76 0.74 0.72
Support 3 (S3) 0.71 0.74 0.71
Support 4 (S4) 0.70